Comment & Sign-on Letters

LUNGevity ensures that the lung cancer community’s interests are represented and heard through a variety of vehicles, including submitting and signing letters to legislators and regulators.

Access to Care & Reimbursement

Food and Drug Administration (FDA)

Support for FDA appointment nominees and initiatives to streamline the cancer drug approval process

Oncology Center of Excellence (OCE) (August 3, 2017)

Enhancing Patient Engagement Efforts Across FDA (June 12, 2017)

Coalition for Clinical Trials Awareness letter (April 7, 2017)

Gottlieb support letter (April 4, 2017)

Gottlieb support letter (March 13, 2017)

Friends of the Cancer Policy Institute letter (January 31, 2017)

Oncology Center for Excellence letter (June 6, 2016)

Califf support letter (February 19, 2016)

Diagnostics Testing Regulation

Urging policymakers to include FDA involvement in the regulation of lab-developed tests

Letter to House on Regulation of Lab-Developed Tests (April 1, 2016)

Letter to Senate on Regulation of Lab-Developed Tests (April 1, 2016)

Letter to the House on Regulation of Lab-Developed Tests (January 24, 2017)

Letter to the Senate on Regulation of Lab-Developed Tests (January 24, 2017)

Federal Research Funding

21st Century Cures

Support for the 21st Century Cures Act, a federal patient-focused bill that would advance the discovery and development of treatments, strengthen the patient voice in the research and regulatory environment, increase funding, and encourage innovation

Letter to House and Senate (November 16, 2016)

print